Literature DB >> 5060402

Levodopa treatment of Parkinson's syndrome. Improved intellectual functioning.

A W Loranger, H Goodell, J E Lee, F McDowell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5060402     DOI： 10.1001/archpsyc.1972.01750200067014

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN： 0003-990X


× No keyword cloud information.
  14 in total

Review 1.  The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.

Authors:  Claudio Da Cunha; Miriam Elizabeth Mendes Angelucci; Newton S Canteras; Susan Wonnacott; Reinaldo N Takahashi
Journal:  Cell Mol Neurobiol       Date:  2002-06       Impact factor: 5.046

Review 2.  Deterioration of dopaminergic pathways and alterations in cognition and motor functions.

Authors:  B Dubois; B Pillon; Y Agid
Journal:  J Neurol       Date:  1992       Impact factor: 4.849

3.  Effects of levodopa therapy in Parkinson's disease. II. Measurement of behavioural changes.

Authors:  R Radbill; G Rosenberg; A Schwartz
Journal:  Can Med Assoc J       Date:  1974-12-07       Impact factor: 8.262

4.  [General intelligence of patients with parkinsonism during L-dopa medication (author's transl)].

Authors:  P Jacobi; P A Fischer; E Schneider
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1974

Review 5.  Critical review of clinical trials in senile dementia--II.

Authors:  J M Orgogozo; R Spiegel
Journal:  Postgrad Med J       Date:  1987-05       Impact factor: 2.401

6.  Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?

Authors:  B Pillon; B Dubois; G Cusimano; A M Bonnet; F Lhermitte; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

7.  Increase in the power of human memory in normal man through the use of drugs.

Authors:  S J Dimond; E M Brouwers
Journal:  Psychopharmacology (Berl)       Date:  1976-09-29       Impact factor: 4.530

8.  Confusion, dementia and anticholinergics in Parkinson's disease.

Authors:  Y de Smet; M Ruberg; M Serdaru; B Dubois; F Lhermitte; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-12       Impact factor: 10.154

9.  Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease.

Authors:  J J Mann; M Stanley; R D Kaplan; J Sweeney; A Neophytides
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-10       Impact factor: 10.154

Review 10.  Diagnostic and pharmacological approaches in Alzheimer's disease.

Authors:  C Hermann; R G Stern; M F Losonzcy; S Jaff; M Davidson
Journal:  Drugs Aging       Date:  1991-03       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.